Response to biologics during the first six months of therapy in biologic-naïve patients with psoriasis predicts risk of disease flares: A danish nationwide study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- 5968
Forlagets udgivne version, 719 KB, PDF-dokument
Early response to treatment with biologics might be important for the stability of psoriasis and long-term outcome. The aim of this study was therefore to assess whether risk of flares and drug survival are associated with disease activity in the first 6 months of treatment of psoriasis with biologics. Biologic-naïve patients from the Danish nationwide registry, DERMBIO, were grouped based on absolute Psoriasis Area and Severity Index (PASI) during the first 6 months of treatment, as: PASI = 0, PASI > 0–≤2, PASI > 2–≤ 4, and PASI > 4. Among 1,684 patients, 746 achieved PASI= 0, 485 PASI > 0–≤2, 246 PASI > 2–≤4, and 207 PASI > 4. Longer flare-free period and drug survival were observed for patients with lower PASI in the first 6 months of treatment (adjusted hazard ratios for flares (95% confidence interval) with PASI= 0 as reference: PASI > 0–≤2 (1.35 (1.11–1.72]), PASI > 2–≤ 4 (2.32 [1.80–2.99]), and PASI > 4 (2.38 [1.80–3.15])). In conclusion, a low PASI in the first 6 months of treatment with biologics in biologic-naïve patients with psoriasis was associated with a more stable disease course, lower risk of flares, and longer drug survival.
Originalsprog | Engelsk |
---|---|
Artikelnummer | adv00357 |
Tidsskrift | Acta Dermato-Venereologica |
Vol/bind | 101 |
Udgave nummer | 1 |
Sider (fra-til) | 1-7 |
Antal sider | 7 |
ISSN | 0001-5555 |
DOI | |
Status | Udgivet - 2021 |
Bibliografisk note
Publisher Copyright:
© 2021, Medical Journals/Acta D-V. All rights reserved.
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
ID: 282470132